Heart transplant including blue book article Flashcards

1
Q

What happens to the nerve supply of the transplanted heart?

A

Absence of sensory, PSNS (from vagus) or SNS (stellate ganglion) innervation- surgically dissected.
Direct-acting vasoactive meds therefore useful but not indirect-acting (responds to circulating catecholamines in an attenuated manner so have blunted responses to exercise, pain & hypovolaemia)
Maximal HR, HR variability & contractility are reduced but coronary autoregulation remains intact

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

What happens to the nerve supply of the transplanted heart? consequences?

A

Absence of sensory, PSNS or SNS innervation.
Can’t respond to indirect-acting agents (ephedrine) or peripheral stimuli to induce haemodynamic changes (eg. carotid massage, laryngoscopy, valsalva)
Direct-acting vasoactive meds therefore useful but not indirect-acting.
However, B effects of epinephrine & norepinephrine are exaggerated; reserve for refractory cardiogenic shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What’s the resting HR for the transplanted heart? why?

A

Generally higher- 90-100bpm than native heart due to loss of predominant vagal tone in normal hearts; goes to “default rate”, HR may vary depending on age of graft

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

do atropine & glycol work on transplanted heart?

A

No- ineffective in treating bradycardia as heart has lost PSNS innervation.
atropine & glycol still retain effects on non cardiac tissues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What may the ecg show in the transplanted heart?

A
  • 2 p waves; one from residual native atrial cuff tissue & one from implanted atrium
  • atrial arrhythmias- eg. 25% develop atrial flutter or fibrillation- lack of vagal tone & increased endogenous catecholamines (conduction delays are the most common arrhythmias in transplanted heart. suture lines predispose to heart blood, ventricular arrhythmias are rare- may be a marker of acute rejection or CAV)
  • R) BBB due to frequent endomyocardial biopsies (5-10% have R) BBB)
  • bradyarrhythmias common (10% require PPM)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the haemodynamic considerations for the transplanted heart?

A

resting HR 90-100
HR response to exercise is blunted, slower to respond
CO drops during exercise
no diurnal variation in BP is seen
no effect with carotid sinus massage & valsalva
in response to drop in preload, no tachycardia response- relies on preload & slow riske in circulating catecholamines to incr HR in response to hypotension
Atrial contraction is asynchronous & atrial filling is impaired, esp LA
Transplanted heart is preload-dependent & relies on adequate intravascular volume; starling response is retained & this becomes important for increasing SV.
Avoid hypoT, VD & acute preload decreases (slow induction, generally avoid neuraxial as denervated heart doesn’t reflexively compensate for haemodynamic changes- any neuraxial pretreated with IVT, very slowly titrated with direct-acting vasopressor running).
No HR response (eg. the Anrep effect of normal heart) to incr afterload
Cognisant that vasodilator drugs (eg. GTN, hydralazine) may have profound effect as no reflex compensatory SNS response- so very carefully titrate propofol with direct-acting vasopressor (metaraminol, phenylephrine) running

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Which vasoactive medications are useful for the transplanted heart?
what need to be careful of though?

A

direct-acting as intrinsic alpha & B receptors in the grafted heart are intact, eg. Adrenaline
The effects of NAdr, Adr & dobutamine may be exaggerated due to increased adrenoceptor density

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are some side-effects of long-term immunosuppression?

A

renal dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What should the preop evaluation focus on for heart transplant?

A
  • cardiac functional status
  • S&S of heart failure
  • signs organ rejection (highest frequency in the first 3/12- SOB, fever, anuria/oliguria, fatigue, fluid retention & weight gain, cardiac allograft vasculopathy)
  • medications: if on long-term corticosteroids (equivalent 5mg PO pred/day) consider 100mg IV hydrocortisone preop
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How treat bradyarrhythmias in the transplanted heart?

A

direct-acting chronotropic agents (isoprenaline, adrenaline) or electrical pacing

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

while neostigmine won’t cause bradycardia, what’s a rare complication of it’s administration in heart transplant?

A

may cause advanced bradycardia, HB & asystole especially if >6/12 post-transplant (reinnervation can occur slowly- SNS innervation at 6-8/12 & PSNS innervation at 1-3yrs post-transplant- variable, unpredictable, LV first & RV later if at all)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what effect does digoxin have on the transplanted heart?

A

no rate-controlling effect but retains inotropic effect

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

can adenosine be given to a heart transplant pt?

A

no; profound & prolonged bradycardia effect on a denervated heart

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Is the starling effect retained in the denervated heart?

A

Yes; it responds to increases in preload with increased SV & CO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Monitoring for heart transplant pt?

A

5-lead ecg
art line

consider more monitoring (CVC, TOE, rarely PAC) if significant blood loss or large IV volume shifts anticipated, particularly if pt has evidence of cardiac dysfunction- R) IJ may have significant scarring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Do pts with heart transplant have the classic presentation during episodes of myocardial ischaemia?

A

No- as no visceral innervation

High index of suspicion for MINS postop

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

do pancuronium & sux impact the HR of a pt with heart transplant?

A

No, but retain extracardiac effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Principles of analgesia in heart transplant patients?

A

important to attenuate any SNS surges perioperatively (high risk perioperative myocardial ischemia, particularly if allograft vasculopathy)
use multi-modal analgesia incl regional
Likely to avoid NSAIDs as high risk renal impairment &HTN
Use BIS with GA to titrate depth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Principles of analgesia in heart transplant patients?

A

important to attenuate any SNS surges perioperatively (high risk perioperative myocardial ischemia, particularly if allograft vasculopathy)
use multi-modal analgesia incl regional
Likely to avoid NSAIDs as high risk renal impairment &HTN
Use BIS with GA to titrate depth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

After what time has the risk of acute rejection diminished post-transplant?

A

12/12, the pt usually stabilised on an immunosuppressive regimen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the considerations wrt immunosuppression in the heart transplant pt?

A
  • Early post-transplant (within the first 3-6/12), risk of immunosuppression-related complications is higher given that high therapeutic levels are targeted, early complications incl: renal dysfunction from calcineurin inhibitors (cyclosporine, tacrolimus), steroid-induced diabetes, steroid-induced myopathy, leukopenia, gingival hyperplasia with cyclosporine, lowering of seizure threshold with calcineurin inhibitors.
  • liaise with pts heart transplant team (multi-D), esp within the first 6-12/12 post-transplant- consider periop immunosuppression regimen & adrenal suppression prophylaxis
  • Ideally, pt should be on a stable immunosuppressive regimen prior to elective surgery
  • risk of acute rejection has diminished after 12/12; primary concerns from this time include allograft vasculopathy (fibrous intimal hyperplasia, the predominant risk for graft dysfunction & chronic rejection in the late post-transplant period), may cause ventricular dysfunction & such pts are @ higher risk for myocardial ischaemia, volume overload or arrhythmias.
  • later, there’s risk of malignancy with chronic immunosuppression incl post-transplant lymphoproliferative disease (may involve airway)- lymphoma more common with a prognosis of under 30% survival @ 5yrs.
  • more than 10% of heart transplant recipients develop de novo malignancy in the first 1-5yrs after transplant (3-4x > background risk), with skin cancers 100-fold incr incidence cf controls. Need rigorous screening for SCC.
  • increased risk infection- ABx prophylaxis, meticulous aseptic technique
  • adrenal suppression prophylaxis: hydrocortisone 100mg at start of surgery followed by infusion 200mg/24hrs, hydrocortisone 100mg/24hrs IVI while NBM, restart usual glucorticoid once eating & drinking if recovery uncomplicated, otherwise double dose for up to 1/52
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are some common medical comorbidities in heart transplant pts & how this impacts periop Mx?

A

they may be on anticoagulants, may have an ICD that needs interrogation/reprogramming

renal: eg. nephrotoxic immunosuppression (calcineurin inhibitors), repeat exposure to contrast0 Ax baseline Cr, eGFR, consider IDC risk/benefit, UO ?0.5mL/kg/hr

pulmonary diseases/airway: may have coexisting restrictive (eg. pectus excavatum) or obstructive airway disease, pre-existing pulm disease prior to transplant, recurrent pneumonias common, Hx prol ventilatory support incr risk postop reap failure. review PFTs & CXR. consider difficult airway risk (eg, if Hx trache or CHD with facial anomalies). Consider opioid-sparing & short-acting analgesics, fully reverse & extubate awake

hepatic disease: eg. from congestive hepatopathy due to pre-transplant HF or due to hepatotoxic meds. Review LFTs incl coats, calculate MELD to determine severity of liver disease

diabetes: steroid-induced, Ax level of control, medication regimen + periop plan, hourly intra-op BGL monitoring, consider first on list & endocrine input

HTN: med management plan

congenital anomalies in pts wth CHD: eg. retrognathia, pectus excavatum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Why may pts with heart transplant be at particular risk of myocardial ischaemia?

A

cardiac allograft vasculopathy- complication in the late post-transplantation period

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What are some airway & ventilation considerations for post-transplant pts?

A

airway:
oral vs nasal (lower infection risk)
oral may still be bleeding risk (gingival hyperplasia with cyclosporine, chronic anticoagulation, increased vascularity of mucosa due to collaterals in pts with CHD)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Which immunosuppressant risks gingival hyperplasia?

A

cyclosporine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Which immunosuppressants may lower seizure threshold?

A

calcineurin inhibitors (cyclosporin, tacrolimus)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

If planning to give stress steroid during surgery, does the pt still need to take their am glucocorticoid?

A

yes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Which ABx need to be avoided due to risk of renal injury when used with calcineurin inhibitors?

A

erythromycin & ahminoglycosides

27
Q

What proportion of pts with heart transplant have R) BBB?

A

up to 75%; it’s very frequent

28
Q

What are potential issues with using the R) IJV for IV access in post-transplant pts?

A

It may have been used a lot already for R) heart Cath & endomyocardial biopsy; may have significant scarring or vessel occlusion

29
Q

Which NMBD may be most appropriate for heart transplant pts?

A

cistatracurium, given organ-independent elimination in a pt population with high incidence of renal or hepatic impairment

30
Q

What are particular postop complications to be cognisant of for heart transplant pts?

A

post-op infections
MINS
exacerbation of chronic renal or hepatic dysfunction

31
Q

For what period after heart transplant should elective surgical procedures generally be deferred?

A

6-12/12 due to greater risk of early complications (acute graft dysfunction, immunosuppression-related complications, infection, exacerbating comorbidities)

32
Q

When may pts with heart transplant get denervation?

A

later down the track, even as soon as 1 year

33
Q

How may acute rejection often manifest?

A

R) heart dysfunction

34
Q

Level of activity/exercise may be an indirect measure of cardiopulmonary function- consideration >12/12

A
35
Q

what may be an issue with sugammadex in heart transplant pt?

A

bradycardia (?mechanism)

36
Q

What’s the median survival of a heart transplant recipient?

A

12 yrs

37
Q

What’s the predominant underlying process in heart transplant recipients? second most common?

A

DCM
ischaemic cardiomyopathy
3rd most common= congenital heart disease

38
Q

What are indications for heart failure?

A

severe functional limitation (NYHA III or IV
arrhythmias refractory to management or recurrent, appropriate shocks
refractory angina
overall failure of medical +/- resynchronisation therapy

39
Q

What are absolute contraindications for heart transplant? and relative?

A
  • uncontrolled diabetes, secondary organ involvement or microvascular complications
  • raised BMI (>30kg/m2)
  • substance abuse (they require 6/12 abstinence from illicit drugs, smoking, ETOH)
  • active or recent malignancy
  • chronic infections (HIV, HBV, HCV) with liver complications
  • active systemic infection
relative= CrCl<40mL/min
liver disease (bili >50mmol/L)
FEV1 < 1L
PASP >60mmHg
non-compliance
40
Q

Factors to consider for heart transplant pre-assessment?

A

pre-op:

Psychological assessment/compliance

Underlying pathology necessitating transplant & therapy up to time of Ax (eg. may be on mechanical support (almost half on waiting list have a VAD) or inotropes while bridging to transplant, pre-exposure to inotropes may blunt responses intra-operatively)

Severity of heart failure & end-organ dysfunction- eg. pulmonary, hepatic congestion, cachexia, CrCl

If pt has a VAD: consider that the pt may be on anticoagulants to prevent device thrombosis, may have acquired VWD due to shear forces, incr bleeding risk/surgical complexity due to prior sternotomy

Discuss with surgical & ICU team the plan for failure to wean from CPB (eg. VA-ECMO, IABP or VAD considered) in advance of the OT.

Assessment incl R) heart cath
CPET- VO2 max helps with timing, VE/VCO2 (ventilatory efficiency) helps predict mortality

intra-op planning/management:
ensure IDC is interrogated & reprogrammed prior to surgery, anti-tachycardia & defibrillator functions disables, backup pacing mode set to optimise CO.
put defibrillator pads on once the defibrillation function has been disabled.

VAD staff?

Ensure X-matched blood immediately available with appropriate CMV compatibility according to donor & recipient status

reverse anticoagulation
continue pulmonary vasodilators (reduces risk RHF & facilitates weaning off CPB)
consider resiting all CVCs intra op to limit infection risk- CVCs on the L) to reserve the R) side for future myocardial biopsy.

Monitoring: cerebral oximetry using NIRS, BIS, art line (may be challenging in VAD pts, use US early), CVC, PA catheter (either prior to or after transplant), TOE & urinary catheter are used.

discuss re: periop immunosuppression: generally a steroid & an immunosuppressant (eg. mycophenolate, anti-TNF alpha)
antibiotic prophylaxis as per local susceptibilities & findings of bronchoscopy on the donor

INDUCTION:
timing of induction coincides with decision from retrieval team that donor heart suitable- judge time for induction, siting lines & surgical access to coincide with organ arrival- minimises ischaemic time. Constant communication btwn retrieval & recipient teams vital for smooth transition & minimal ischaemic time (usually managed by a coordinator)
goal- preserve biventricular performance- judicious admin of induction while maintain SVR, normoxaemia & normocarbia- pts with end-stage HF have fixed SV that’s preload dependent.
consider midaz 1-5mg slowly titrated, fent 2-4microg/kg, propofol 0-1mg/kg, NDMR with fast onset.
ideally etomidate in haemodynamically-compromised but the dose & speed of admin is the most relevant factor.
Avoid N2O (PVR)

During OT:
heparinisation in usual fashion prior to CPB- mindful that pts with VAD have incr bleeding risk due to prior sternotomy
CPB generally via R) atrial cannulation, the PA catheter should be withdrawn prior to this stage.
Outflow graft of the VAD clamped & device turned off before cannulate the aorta
minimal surgical handling of the heart prior to cannulation to avoid dislodging thrombus that could’ve formed with chronically low CO

TxA as routine antifibrinolytic, cell salvage once weaned from CPB

Weaning from CPB can be challenging (eg. donor factors such as ischaemic time, recipient factors such as raised PVR, bleeding, prolonged CPB & subsequent vasoplegia)
consideration of pharmacodynamic differences with the transplanted heart
balance btwn filling the new preload-dependent heart & avoiding RV over-distension (RV failure= the most common reason for early failure to wean from CPB- esp if raised PVR & naive RV- optimising ventilation & NO or PDE-inhibitors may help).

41
Q

What are some benefits that have been shown from use of a VAD while on transplant waiting list?

A

improved conditioning: increased VO2 peak, improved 6MWT
improve renal function
allows moderate exercise to improve body weight while on the waiting list

42
Q

Why is increased PVR associated with worsened outcomes for heart transplant? How is pulm HTN diagnosed & severity assessed for consideration of heart transplant?

A

the transplanted heart isn’t trained to cope with high RV afterload, so it’s vital to identify & treat pts with pulm HTN prior to listing for transplantation

right heart catheterisation

43
Q

How is PVR derived?

A

using poiseuille’s law- pressure difference divided by blood flow.

PVR = (MPAP - PCWP) / CO

44
Q

How is PAWP taken?

A

PA catheter floated into PA, wedged into pulm artery forming continuous column of blood to the LA- the pressure will drop & equalise as the balloon inflated- surrogate for LA pressure.
average of 3 readings taken at end of normal expiration (coincides with FRC, intra- & extra- thoracic pressure equalised)

45
Q

What’s the Transpulmonary gradient & what’s it useful for?

A

MPAP - PCWP, useful for diagnosing pulm HTN “out of proportion” for what may be expected for a given LAP in pts with LV failure or mitral disease- high values >15mmHg are of concern while values <11mmHg are associated with improved outcomes @ 1 year

pts with PVR of >2.5 woods units & TPG >15mmHg are at 3x risk of RHF & early mortality following transplant (donor heart not used to such high R)-sided pressures)
these pts should undergo a “vasoreactivity test”- giving pulm vasodilators to assess for reversibility of PVR during RHC

Pts can be put on a 6-8 week pulmonary vasodilator trial prior to reassessment, eg. SNP, milrinone, NO, prostaglandins, sildefanil

If the pulm HTN is reversible, equivocal outcomes after transplant

46
Q

Which values are measured & derived from R) heart catheterisation?

A
Measured:
CO- via thermodilution technique- average of 3 readings, may be inaccurate if shunt
SvO2
PAP
PAWP (average over 3 readings)
RAP
RVP
Derived:
cardiac index (referenced to BSA)
transpulmonary pressure gradient (MPAP - PAWP)
diastolic pressure gradient (DPAP-PAWP)
PVR (from MPAP-PAWP / CO)
47
Q

Which values from CPET are useful in decision-making for transplant workup? what’s the predictive value of these tests?

A

VO2 peak

VE/VCO2 slope (which is the ability to increase minute ventilation in response to increased CO2 production)- a measure of ventilatory efficiency, ie. excess increase in minute ventilation (VE) in response to increased CO2 production (VCO2) (steeper slope) poorer prognosis

VO2 peak >14mL/kg/min has equivocal 1-2 year outcomes cf those who undergo transplant so this helps guide timing of transplant. This test is limited by effort or symptoms (premature test cessation). since it’s a per kg test it may underestimate performance in pts with increased BMI & is negatively effected by B=blocker therapy. Oz guidelines recommend heart transplant consideration if peak VO2 is <12mL/kg/min.

Ventilatory efficiency (steeper slope) is the strongest CPET predictor of mortality in pts with heart failure & is independent of B-blockers, sex, age & VO2 peak in predicting mortality.

48
Q

Limitations of VO2 max

A

impacted by pt effort/symptoms
it’s a per kg test so may underestimate performance in pts with increased BMI
test is negatively impacted by B-blocker therapy

49
Q

How does brainstem death impair myocardial performance?

A

prior to brainstem death, ANS activation may –> profound VC, increased afterload, redistribution of blood volume & arrhythmias. 40% of brain-death donors have echo evidence of impaired cardiac function.
following the catecholamine storm a period of vasoplegia often develops, with end-organ perfusion that may further impair myocardial function.

49
Q

How does brainstem death impair myocardial performance?

A

prior to brainstem death, ANS activation may –> profound VC, increased afterload, redistribution of blood volume & arrhythmias. 40% of brain-death donors have echo evidence of impaired cardiac function.
following the catecholamine storm a period of vasoplegia often develops, with end-organ perfusion that may further impair myocardial function.

50
Q

What’s warm ischaemic time? and cold ischaemic time?

A

from aortic XC application until cooling for storage added to time taken from rewarming the heart and anastomosing it to the recipient.
cold ischaemic time from when the cold cardioplegia solution is employed until warm repercussion solution is administered prior to implantation.

51
Q

What’s the ideal “total” ischaemic time for heart transplant?

A

<4 hrs- this can be extended if the donor younger.
>6hrs is an independent risk factor for poor outcome (but isolated paediatric cases have shown good outcomes with ischaemic times exceeding 8hrs)

52
Q

What’s the ideal “total” ischaemic time for heart transplant?

A

<4 hrs- this can be extended if the donor younger.
>6hrs is an independent risk factor for poor outcome (but isolated paediatric cases have shown good outcomes with ischaemic times exceeding 8hrs)

53
Q

What are some “ideal donor” characteristics for heart transplant?

A

gender & racial match, body size match (within 20-30% of recipients size)
no renal impairment or underlying chronic infection
young, non-smoking donor
short ischaemic time (<4hrs)
low PVR, structurally normal heart, LVEF >45%

54
Q

After separated from bypass, reflect the PA catheter- then what’s the mnemonic for the first 24hrs in ICU?

A

Ph optimised
Reduce PVR (milrinone, sildenafil, epoprostenol, nitric oxide)
Oxygenation, avoid hypoxia
Temp (normothermia)
Euvolemia
CVP- watch for sudden rises suggesting RV failure
Tamponade- high suspicion, low threshold for Mx
Rate- paced at 80-100bpm
Ventilation- normal PaCO2

55
Q

What’s the major cause of death within 30 days following heart transplant? rate? first-line therapy?

A

primary graft dysfunction- defined as low CO (cardiac index <2L/min/m2) occurring within 24hrs of surgery with no other secondary cause
9-12%, biventricular then RV followed distantly by LV dysfunction being the cause.

VA ECMO= Rx of choice as 89% of pts successfully wean from it after PGD, other Rx= IABP, VAD.

56
Q

What are some examples of secondary graft dysfunction?

A

an umbrella term when the cause of graft dysfunction has been identified- incl:

  • hyper acute rejection (due to anti-donor antibodies, 70% mortality but incidence fallen with ABO-compatibility testing, HLA matching, gender/race matching & aggressive early immunosuppression)
  • rejection due to pulm HTN
  • surgical complications eg. bleeding
57
Q

What’s the leading cause of death 1-3 years after cardiac transplant? gold standard Ix?

A

cardiac allograft vasculopathy
an accelerated form of intimal hyperplasia along entire length of transplanted coronaries, is progressive & affects all donated vessels (remnant recipient vessels spared).
has immune-mediated & non-immune (eg. hyperlipidaemia) elements
Difficult to diagnose as heart transplant pts don’t demonstrate classical symptoms of MI.
suspicion raised by new RWMAs, diastolic dysfunction, new arrhythmias (esp. ventricular)

Intravenous ultrasonography= gold standard, costly & time-consuming- only use if angiography yields no positive findings

58
Q

How often & what’s the anaesthesia for endomyocardial biopsies?

A

regularly in first year post-transplant, to Ax for evidence of rejection- day-case under LA by R) IJ

59
Q

What happens to the HR & CO of the transplanted heart in response to exercise?

A

HR blunted response, slower increase

reduce CO

60
Q

Is ANP production affected in the transplanted heart?

A

no

61
Q

what are the effects of metaraminol & phenylephrine on pts w heart transplant?

A

effective, no reflex bradycardia

62
Q

is ephedrine effective in heart transplant pts?

A

decreased effect- indirect mechanism

63
Q

is lignocaine effective for the transplanted heart?

A

yes

64
Q

are beta blockers effective for the transplanted heart?

A

yes but caution as heart is reliant on circulating catecholamines to increase CO

65
Q

are CCBs effective on transplanted heart?

A

yes but significant -ve inotropy